[1] Hwang D, Wang HL. Medical contraindications to implant therapy :Part II : Relative contraindications [J]. Implant Dent, 2007, 16(1)∶13- 23 [2] BornsteinM M, Cionca N, M ombelliA. Systemic conditions and treatments as risks for implant therapy [J]. Int J Oral Maxillofac Implants,2009,24(1)∶12- 27 [3] 蒋晔,丁翔宇, 蒋懿等, 雷尼酸锶药效学与药动学的研究进展[J].中国医院药学杂志,2006,26(02)∶197-199 [4] 马慧萍,贾正平,葛欣.骨质疏松症的药物防治研究现状[J].中国药师,2004,7(10)∶816-818 [5] K asug iS. Dental implant treatment to osteoporosis patients [J]. C lin Calcium, 2006, 16(2)∶348- 353 [6] Yunfeng Li, Ying Gao, Additive effects of estrogen replacement therapy and bisphosphonates on osseointegration of hydroxyapatite-coated itanium screws in ovariectomized rats [J]. Oral and maxillofacial implants, 2010, 109(5)∶700-705 [7] Bonnel ye E, Chabadel A, Sal tel F, et al. Dual effect of strontium ranelate: stimuation of osteoblast differentiation and inhibition of osteoclast formation and resorption i n vitro [J]. Bone, 2008, 42(1)∶129-138 [8] Ammann P, Shen V, Robin B, et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats [J]. Bone Miner Res, 2004, 19(12)∶2012-2020 |